Patent Portfolio

Lpath has achieved a broad and deep intellectual-property position in the bioactive lipid area. The Company's patent portfolio is comprehensive with over 50 issued or pending patents in the U.S. alone, with corresponding international filings. A number of our issued patents and pending patent applications concern the use of reagents and methods designed to interfere with the actions of bioactive lipids involved in human disease. Our intellectual-property portfolio includes compositions of matter that specifically bind to sphingolipids and sphingolipid metabolites. These reagents, including antibodies, have already found, or might find in the future, use in the diagnosis and treatment of various diseases and disorders, including cardiovascular/cerebrovascular disease, cancer, inflammation, autoimmune disorders, ocular disease and angiogenesis. The Company has also obtained issued claims on sphingolipid targets (e.g., receptors, signaling sphingolipids) and methods for using such targets in drug discovery screening efforts. In short, the Company believes that its patent estate will provide broad, commercially significant coverage of antibodies, receptors, enzymes, or other moieties that bind to a lysolipid (or a sphingolipid metabolite), for diagnostic, therapeutic, or screening purposes.

The following is a partial list of U.S. patents and published U.S. patent applications owned by the Company.

U.S. Issued Patents (partial list)

  1. 8,222,373 Humanized antibodies and compositions for binding sphingosine-1-phosphate
  2. 8,158,124 Compositions and methods for binding lysophosphatidic acid
  3. 8,067,549 Humanized antibodies and compositions for binding sphingosine-1-phosphate
  4. 8,026,342 Compositions and Methods for Binding Sphingosine-1-Phosphate 
  5. 8,025,877 Methods of Using Humanized Antibodies and Compositions for Binding Sphingosine-1-Phosphate
  6. 7,956,173 Nucleic Acids Coding for Humanized Antibodies and Compositions for Binding Sphingosine-1-Phosphate
  7. 7,901,682 Compositions & Methods for the Treatment and Prevention of Cancer, Angiogenesis, and Inflammation
  8. 7,862,812 Methods for Decreasing Immune Response and Treating Immune Conditions
  9. 7,829,674 Compositions and Methods for Binding Sphingosine-1-Phosphate
  10. 7,794,713 Compositions and Methods for the Treatment and Prevention of Hyperproliferative Diseases
  11. 7,169,390 Compositions and Methods for the Treatment and Prevention of Cancer, Angiogenesis, and Inflammation
  12. 6,881,546 Compositions & Methods for the Treatment & Prevention of Cardiovascular Diseases & for Identifying Agents therapeutic Therefor
  13. 6,858,383 Compositions & Methods for the Treatment and Prevention of Cardiovascular Diseases and for Identifying Agents Therapeutic Therefor
  14. 6,716,595 Method for Detecting Sphingosine-1-Phosphate (S1P) For Cancer Detection
  15. 6,534,323 Methods for Early Detection of Heart Disease
  16. 6,534,322 Kits for Early Detection of Heart Disease
  17. 6,500,633 Method of Detecting Carcinomas
  18. 6,485,922 Methods for Detecting Compounds Which Modulate the Activity of an LPA Receptor
  19. 6,461,830 Determining Existence of Preeclampsia in Pregnancies by Measuring Levels of Glycerophosphatidyl Compounds, Glycerophosphatidycholine, Lysophospholipids and Lysophosphatidycholine
  20. 6,448,023 Enzyme Method for Detecting Sphingosine-1-Phosphate (S1P)
  21. 6,380,177 LPA Analogs as Agonists of the EDG2 LPA Receptor
  22. 6,248,553 Enzyme Method for Detecting Lysophospholipids and Phospholipids and for Detecting and Correlating Conditions Associated With Altered Levels of Lysophospholipids
  23. 6,210,976 Methods for Early Detection of Heart Disease

U.S. Patents pending (partial list)

  1. Pending Methods for decreasing immune response and treating immune conditions
  2. Pending Compositions & methods for the treatment and prevention of cancer, angiogenesis, and inflammation
  3. Pending Compositions, methods and medical devices for the treatment and prevention of myocardial ischemia and acute coronary syndrome
  4. Pending Compositions and methods for binding sphingosine-1-phosphate
  5. Pending Compositions and methods for the treatment and prevention of ocular conditions
  6. Pending Novel bioactive lipid derivatives, and methods of making and using same
  7. Pending Immune-derived moieties reactive against bioactive lipids, and methods of making and using same
  8. Pending Methods and reagents for detecting bioactive lipids
  9. Pending Immune-derived moieties reactive against lysophosphatidic acid